Cargando…

Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma

Neutrophil extracellular traps (NETs) are web-like structures consisting of DNA, histones and granule proteins, released from neutrophils in thrombus formation, inflammation, and cancer. We asked if plasma levels of the NET markers myeloperoxidase (MPO)-DNA and citrullinated histone H3 (H3Cit)-DNA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zenlander, Robin, Havervall, Sebastian, Magnusson, Maria, Engstrand, Jennie, Ågren, Anna, Thålin, Charlotte, Stål, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429678/
https://www.ncbi.nlm.nih.gov/pubmed/34504150
http://dx.doi.org/10.1038/s41598-021-97233-3
_version_ 1783750579469680640
author Zenlander, Robin
Havervall, Sebastian
Magnusson, Maria
Engstrand, Jennie
Ågren, Anna
Thålin, Charlotte
Stål, Per
author_facet Zenlander, Robin
Havervall, Sebastian
Magnusson, Maria
Engstrand, Jennie
Ågren, Anna
Thålin, Charlotte
Stål, Per
author_sort Zenlander, Robin
collection PubMed
description Neutrophil extracellular traps (NETs) are web-like structures consisting of DNA, histones and granule proteins, released from neutrophils in thrombus formation, inflammation, and cancer. We asked if plasma levels of the NET markers myeloperoxidase (MPO)-DNA and citrullinated histone H3 (H3Cit)-DNA, are elevated in liver cirrhosis and hepatocellular carcinoma (HCC) and if the levels correlate with clinical parameters. MPO-DNA, H3Cit-DNA, and thrombin–antithrombin (TAT) complex, as a marker of coagulation activity, were measured using ELISA in plasma from 82 patients with HCC, 95 patients with cirrhosis and 50 healthy controls. Correlations were made to clinical parameters and laboratory data and patients were followed for a median of 22.5 months regarding thrombosis development. H3Cit-DNA was significantly (p < 0.01) elevated in plasma from cirrhosis (66.4 ng/mL) and HCC (63.8 ng/mL) patients compared to healthy controls (31.8 ng/mL). TAT levels showed similar pattern (3.1, 3.7, and 0.0 µg/mL respectively, p < 0.01). MPO-DNA was significantly (p < 0.01) elevated in cirrhosis patients (0.53 O.D.) as compared to controls (0.33 O.D.). Levels of MPO-DNA and H3Cit-DNA correlated positively with Child–Pugh and MELD score. TAT was increased in all Child–Pugh and MELD groups. In multivariable logistic regression, Child B and C liver cirrhosis were independent predictors of elevated H3Cit-DNA in plasma. Levels of MPO-DNA and H3Cit-DNA were similar in patients with or without history of thrombosis, or thrombus formation during follow-up. In conclusion, plasma markers of NET formation are elevated in liver cirrhosis and correlate to the degree of liver dysfunction in patients with liver cirrhosis and/or HCC. The presence of HCC did not further increase the plasma levels of NET markers as compared to patients with cirrhosis only.
format Online
Article
Text
id pubmed-8429678
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84296782021-09-13 Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma Zenlander, Robin Havervall, Sebastian Magnusson, Maria Engstrand, Jennie Ågren, Anna Thålin, Charlotte Stål, Per Sci Rep Article Neutrophil extracellular traps (NETs) are web-like structures consisting of DNA, histones and granule proteins, released from neutrophils in thrombus formation, inflammation, and cancer. We asked if plasma levels of the NET markers myeloperoxidase (MPO)-DNA and citrullinated histone H3 (H3Cit)-DNA, are elevated in liver cirrhosis and hepatocellular carcinoma (HCC) and if the levels correlate with clinical parameters. MPO-DNA, H3Cit-DNA, and thrombin–antithrombin (TAT) complex, as a marker of coagulation activity, were measured using ELISA in plasma from 82 patients with HCC, 95 patients with cirrhosis and 50 healthy controls. Correlations were made to clinical parameters and laboratory data and patients were followed for a median of 22.5 months regarding thrombosis development. H3Cit-DNA was significantly (p < 0.01) elevated in plasma from cirrhosis (66.4 ng/mL) and HCC (63.8 ng/mL) patients compared to healthy controls (31.8 ng/mL). TAT levels showed similar pattern (3.1, 3.7, and 0.0 µg/mL respectively, p < 0.01). MPO-DNA was significantly (p < 0.01) elevated in cirrhosis patients (0.53 O.D.) as compared to controls (0.33 O.D.). Levels of MPO-DNA and H3Cit-DNA correlated positively with Child–Pugh and MELD score. TAT was increased in all Child–Pugh and MELD groups. In multivariable logistic regression, Child B and C liver cirrhosis were independent predictors of elevated H3Cit-DNA in plasma. Levels of MPO-DNA and H3Cit-DNA were similar in patients with or without history of thrombosis, or thrombus formation during follow-up. In conclusion, plasma markers of NET formation are elevated in liver cirrhosis and correlate to the degree of liver dysfunction in patients with liver cirrhosis and/or HCC. The presence of HCC did not further increase the plasma levels of NET markers as compared to patients with cirrhosis only. Nature Publishing Group UK 2021-09-09 /pmc/articles/PMC8429678/ /pubmed/34504150 http://dx.doi.org/10.1038/s41598-021-97233-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zenlander, Robin
Havervall, Sebastian
Magnusson, Maria
Engstrand, Jennie
Ågren, Anna
Thålin, Charlotte
Stål, Per
Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
title Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
title_full Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
title_fullStr Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
title_full_unstemmed Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
title_short Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
title_sort neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429678/
https://www.ncbi.nlm.nih.gov/pubmed/34504150
http://dx.doi.org/10.1038/s41598-021-97233-3
work_keys_str_mv AT zenlanderrobin neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma
AT havervallsebastian neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma
AT magnussonmaria neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma
AT engstrandjennie neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma
AT agrenanna neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma
AT thalincharlotte neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma
AT stalper neutrophilextracellulartrapsinpatientswithlivercirrhosisandhepatocellularcarcinoma